Exabis Library
Welcome to the e-CCO Library!
P600: Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P600: Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P600: Serologic response to COVID-19 vaccines in IBD patients: a prospective study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P600: Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study from Finland
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P601: Are Inflammatory Bowel Disease patients’ expectations met by dietetic services?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P601: Can Amitriptylin improve the quality of life in patients with Crohn's disease?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P601: Differential cytokine profiles and drop of faecal calprotectin for prediction of primary response to infliximab induction therapy in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P601: Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary project
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P601: Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P601: Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P602 Changes in emotional health and work-related outcomes in patients with moderate to severe ulcerative colitis 1 year after diagnosis: Results from the MOSAIK cohort in Korea
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P602: Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P602: CD-TREAT a novel dietary therapy of active Crohn’s disease using the exclusive enteral nutrition paradigm
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P602: Clinical/biochemical predictors of response to anti-TNFa therapies in a tertiary referral centre
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P602: Factors associated with discontinuation of initial and subsequent tumour necrosis factor inhibitors in a large paediatric inflammatory bowel disease observational cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P602: Tofacitinib treatment prevents post-operative recurrence of Crohn’s Disease modeled by ileocecal resection in HLA-B27 transgenic rats.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P602: Vedolizumab subcutaneous influencing disease course in Constant-care app solution
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P603 Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P603: Hospitalisation risk and reintervention after ileocolonic resection with anastomosis in patients with Crohn's disease. Results from the PRACTICROHN study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM